Common Stock, $0.001 par value
- Symbol
- SBEV
- Exchange
- NYSEAMER
- Classification
- COMMON
- Status
- Historical · closed Jun 4, 2026
Current Report · Items 7.01, 9.01 · 8-K
Endovia Health Sciences, Inc.
EDVANYSE_AMERICANEQUITYCurrent
Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On August 5, 2026, the Company issued a press release announcing its entry into the Collaboration Agreement with Lupvindol Biosciences Ltd. for the development and advancement of CannEpil® for veterinary uses. A copy of the press release is furnished as Exhibit 99.1 of this Current Report on Form 8-K.…
Company context
The Company is a Nevada corporation that was historically seeking to identify, acquire, and build early stage or under-valued beverage brands that have strong growth potential within its distribution system. During the current fiscal year beginning January 1, 2026, the Company has moved away from beverages and is focusing on the cannabinoid and health and wellness economy businesses.
Current securities
Registered securities in this filing
SPLASH BEVERAGE GROUP, INC. · 8-K · Filed 2026-08-05
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure
On August 5, 2026, the Company issued a press release
announcing its entry into the Collaboration Agreement with Lupvindol Biosciences Ltd. for the development and advancement of CannEpil®
for veterinary uses. A copy of the press release is furnished as Exhibit 99.1 of this Current Report on Form 8-K.
The information in this Item 7.01 (including Exhibit
99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”)
or otherwise subject to the liabilities under such section, and shall not be deemed to be incorporated by reference into any filing of
the Company under the Securities Act of 1933 or the Exchange Act.
Filed exhibits (1)
EX-99.1 2 e7828_ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 SPLASH BEVERAGE GROUP PARTNERS WITH VETERAN CANNABINOID DRUG-DEVELOPMENT TEAM TO ADVANCE CANNEPIL® THROUGH FDA VETERINARY PATHWAY Collaboration with Lupvindol Biosciences will initially target companion-animal oncology and chronic pain management Splash retains ownership of resulting data, intellectual property and commercialization rights FORT LAUDERDALE, Fla., August 5, 2026 - Splash Beverage Group, Inc. (NYSE American: SBEV) (“Splash” or the “Company”) today announced that it has entered into a strategic development and collaboration agreement with Lupvindol Biosciences Ltd. to advance CannEpil® as a potential FDA-regulated veterinary pharmaceutical product for companion-animal oncology and chronic pain management. The milestone-driven program is designed to advance CannEpil through the U.S. Food and Drug Administration’s Center for Veterinary Medicine, beginning with the Investigational New Animal Drug (“INAD”) process and progressing toward potential conditional approval pursuant to Section 571 of the Federal Food, Drug, and Cosmetic Act (“Conditional Approval”). Canine applications are expected to represent the ini…
Open exhibit ↗